TNF and melanoma: Major evidence applies to the incident cancer risk on immunosuppressed patients and it demonstrates an increased risk of lymphoma and nonmelanoma skin cancer (NMSC) in patients on treatments with thiopurines [5,6,7,8,9], while melanoma incidence is increased 1.32-fold in patients under TNFα inhibitors [10].